ES2111104T3 - Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer. - Google Patents

Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
ES2111104T3
ES2111104T3 ES93113775T ES93113775T ES2111104T3 ES 2111104 T3 ES2111104 T3 ES 2111104T3 ES 93113775 T ES93113775 T ES 93113775T ES 93113775 T ES93113775 T ES 93113775T ES 2111104 T3 ES2111104 T3 ES 2111104T3
Authority
ES
Spain
Prior art keywords
nadh
nadph
medicine
treatment
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93113775T
Other languages
English (en)
Inventor
Jorg Univ-Prof Ddr Birkmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIRKMAYER JORG UNIV PROF DDR
Original Assignee
BIRKMAYER JORG UNIV PROF DDR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIRKMAYER JORG UNIV PROF DDR filed Critical BIRKMAYER JORG UNIV PROF DDR
Application granted granted Critical
Publication of ES2111104T3 publication Critical patent/ES2111104T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

UTILIZACION DE LA FORMA REDUCIDA DE NICOTINAMIDA-ADENINADINUCLEOTIDO (NADH), DE LA FORMA REDUCIDA DE NICOTINAMIDA-ADENINADINUCLEOTIDFOSFATO (NADPH) O DE UNA SAL TOLERABLE FISIOLOGICAMENTE DE LAS MISMAS PARA LA PREPARACION DE UN MEDICAMENTO/MEDICINA PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.
ES93113775T 1992-09-30 1993-08-27 Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer. Expired - Lifetime ES2111104T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232899A DE4232899C2 (de) 1992-09-30 1992-09-30 Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer

Publications (1)

Publication Number Publication Date
ES2111104T3 true ES2111104T3 (es) 1998-03-01

Family

ID=6469304

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93113775T Expired - Lifetime ES2111104T3 (es) 1992-09-30 1993-08-27 Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer.

Country Status (16)

Country Link
US (1) US5444053A (es)
EP (1) EP0590321B1 (es)
JP (1) JP3384847B2 (es)
CN (1) CN1053341C (es)
AT (1) ATE162076T1 (es)
AU (1) AU664768B2 (es)
CA (1) CA2105912C (es)
DE (2) DE4232899C2 (es)
DK (1) DK0590321T3 (es)
ES (1) ES2111104T3 (es)
GR (1) GR3026120T3 (es)
IL (1) IL106785A (es)
MX (1) MX9306049A (es)
NO (1) NO303482B1 (es)
TW (1) TW231268B (es)
ZA (1) ZA936327B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
JP4219591B2 (ja) * 2000-04-28 2009-02-04 美津濃株式会社 フットウエアの緊締構造
AU2002256422A1 (en) * 2001-05-02 2002-11-11 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
DE10254995B4 (de) * 2002-11-26 2005-02-10 Juelich Enzyme Products Gmbh Verfahren zur enzymatischen Reduktion von NAD und NADP
US7034011B2 (en) * 2002-12-03 2006-04-25 Kyowa Hakko Kogyo Co., Ltd. Method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate
US20040126751A1 (en) * 2002-12-27 2004-07-01 Birkmayer Jorg G.D. Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
US9186350B2 (en) * 2011-07-12 2015-11-17 Gdb Patent Holdings, Llc Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication
EP2574339A1 (de) 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
CN103340890B (zh) * 2013-06-08 2016-04-27 苏州人本药业有限公司 Nadph作为制备用于防治脑缺血性中风药物方面的应用
WO2019028877A1 (zh) * 2017-08-11 2019-02-14 邦泰生物工程(深圳)有限公司 一种含有nadh和nadph的组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814339A (en) * 1986-02-11 1989-03-21 Advanced Biologics, Inc. Treatment for Alzheimer's disease
JP2736103B2 (ja) * 1988-03-01 1998-04-02 ヴァルター・ビルクマイヤー パーキンソン症候群の治療用医薬、およびその製造方法
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels

Also Published As

Publication number Publication date
DK0590321T3 (da) 1998-09-14
ZA936327B (en) 1994-03-22
IL106785A0 (en) 1993-12-08
NO303482B1 (no) 1998-07-20
AU4488793A (en) 1994-04-14
JPH06192106A (ja) 1994-07-12
IL106785A (en) 1997-09-30
EP0590321B1 (de) 1998-01-14
CA2105912C (en) 2000-11-14
CA2105912A1 (en) 1994-03-31
EP0590321A1 (de) 1994-04-06
DE4232899A1 (de) 1994-03-31
TW231268B (es) 1994-10-01
MX9306049A (es) 1994-05-31
CN1089474A (zh) 1994-07-20
DE59307982D1 (de) 1998-02-19
JP3384847B2 (ja) 2003-03-10
ATE162076T1 (de) 1998-01-15
GR3026120T3 (en) 1998-05-29
CN1053341C (zh) 2000-06-14
NO933321L (no) 1994-04-05
US5444053A (en) 1995-08-22
DE4232899C2 (de) 1995-02-23
NO933321D0 (no) 1993-09-17
AU664768B2 (en) 1995-11-30

Similar Documents

Publication Publication Date Title
PT87542A (pt) Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease
ES2111104T3 (es) Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer.
AU3401093A (en) Therapeutic agent for threatened abortion
BR9105183A (pt) Medicamento antidepressivo
HUT61895A (en) Process for producing pharmaceutical composition against cancer and aids
KR100194995B1 (ko) 관상동맥성 심장질환,동맥경화증 및(또는)지방단백질 대사 이상 치료용 약제

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 590321

Country of ref document: ES